Journal of Medical Toxicology最新文献_第7页

The American College of Medical Toxicology (ACMT) Commitment to Diversity, Equity, and Inclusion in Medical Toxicology. 美国医学毒理学学院 (ACMT) 对医学毒理学多样性、公平性和包容性的承诺。

IF 2.5 4区医学

Journal of Medical Toxicology Pub Date : 2024-07-11 Epub Date: 2024-07-08 DOI: 10.1007/s13181-024-01021-0

Peter D Akpunonu, Richard J Church, Kavita M Babu, Trevonne M Thompson

引用次数: 0

An Internet Snapshot Survey Assessing the sale of Synthetic Cannabinoid Receptor Agonists for use with Electronic Vaping Devices. 一项互联网快照调查，评估用于电子吸食器的合成大麻素受体激动剂的销售情况。

IF 2.5 4区医学

Journal of Medical Toxicology Pub Date : 2024-07-11 Epub Date: 2024-06-05 DOI: 10.1007/s13181-024-01013-0

Allon Gould, Paul I Dargan, David M Wood

{"title":"An Internet Snapshot Survey Assessing the sale of Synthetic Cannabinoid Receptor Agonists for use with Electronic Vaping Devices.","authors":"Allon Gould, Paul I Dargan, David M Wood","doi":"10.1007/s13181-024-01013-0","DOIUrl":"10.1007/s13181-024-01013-0","url":null,"abstract":"Introduction: Synthetic cannabinoid receptor agonists (SCRAs) are associated with significant toxicity and are increasingly used in electronic vaping devices. We assessed the availability of SCRA vaping products to UK purchasers on the surface web.Methods: An internet snapshot survey was performed between October 2022 and January 2023 on 'google.com' using the search terms \"buy c-liquid vape\", \"buy herbal incense vape liquid\", \"buy cannabis vape liquid\", \"buy hashish vape liquid\", \"buy K2 vape liquid\".Results: 62 websites selling 128 SCRA vaping brands were identified. Most were purportedly based in the USA (41 websites, 66%) and most sold other controlled substances. Purchase incentives offered included discreet packaging (38, 61%), discounts for bulk purchase (34, 55%) and tracked delivery (30, 48%). Many websites stated SCRA products were: not for human consumption (41, 66%), for research purposes only (15, 24%), or legal (28, 45%). Websites sold a median (IQR) of 16 (7-25) SCRA vaping brands. Almost all were bottles of vaping liquid (1220/1225, 99.6%). The most common bottle size was 5mL (60%), the median (IQR) total volume of SCRA liquid per sale was 50mL (10-200mL). Median (IQR) price was £3.39/mL (£2.01/mL- £5.29/mL). Price decreased with increasing volume purchased (£6.58/mL for ≤ 5mL, £1.60/mL for > 200mL).Conclusion: SCRA vaping products are easily obtainable online, in both small and bulk quantities. Information provided to purchasers on safety and legality is lacking or misleading. Further studies are needed to confirm the chemistry of these products. Policymakers should consider steps to limit the potential harm caused by the purchase and use of these products.","PeriodicalId":16429,"journal":{"name":"Journal of Medical Toxicology","volume":" ","pages":"271-277"},"PeriodicalIF":2.5,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11288222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141262109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biostatistics and Epidemiology for the Toxicologist: Types of Data and Why It Matters. 毒理学家的生物统计学和流行病学：数据类型及其重要性。

IF 2.5 4区医学

Journal of Medical Toxicology Pub Date : 2024-07-11 Epub Date: 2024-06-05 DOI: 10.1007/s13181-024-01015-y

Sanjay Mohan, Elise Perlman, Mark K Su

引用次数: 0

GLP-1 Receptor Agonist Exposures Are Increasingly Common and Generally Associated with Mild Symptoms: A Single Poison Center Experience. GLP-1 受体激动剂暴露越来越常见，且通常伴有轻微症状：单一毒物中心的经验。

IF 2.5 4区医学

Journal of Medical Toxicology Pub Date : 2024-07-11 Epub Date: 2024-06-11 DOI: 10.1007/s13181-024-01008-x

Stacy Marshall, Erin Ryan, Jessica Rivera, Lindy Reynolds, Suhkshant Atti

{"title":"GLP-1 Receptor Agonist Exposures Are Increasingly Common and Generally Associated with Mild Symptoms: A Single Poison Center Experience.","authors":"Stacy Marshall, Erin Ryan, Jessica Rivera, Lindy Reynolds, Suhkshant Atti","doi":"10.1007/s13181-024-01008-x","DOIUrl":"10.1007/s13181-024-01008-x","url":null,"abstract":"Introduction: Glucagon-like peptide-1 receptor agonist use has increased over the last decade for glycemic control in type 2 diabetes mellitus, cardiovascular risk reduction, and weight loss. Clinical trials indicate that gastrointestinal adverse effects are commonly experienced and severe hypoglycemia is rare; however, there is little data regarding glucagon-like peptide-1 receptor agonist in overdose.Methods: We performed a retrospective chart review evaluating and characterizing glucagon-like peptide-1 receptor agonist exposures reported to a single poison center between 2006 and 2023. Patient demographics, circumstances of exposure, clinical effects, and outcomes were abstracted from charts. Descriptive statistics were utilized to summarize demographic information and clinical factor data.Results: A total of 152 charts met inclusion criteria. Therapeutic errors accounted for 91% of exposures. Most patients (67%) reported no symptoms, although not all patients were followed to a definitive outcome. Nausea, vomiting, generalized weakness, and abdominal pain were the predominant symptoms reported. Most patients (62%) were monitored and closely followed in the home setting. Hypoglycemia was rare but occurred in the setting of a single agent glucagon-like peptide-1 receptor agonist exposure in two patients. Two additional patients who developed hypoglycemia involved co-administration of insulin. 21% of the exposures were related to errors on initial use of the pen.Conclusion: Exposures to glucagon-like peptide-1 receptor agonist have increased substantially over the years. Effects from an exposure tended to be mild and primarily involve gastrointestinal symptoms. Hypoglycemia was rare. Therapeutic and administration errors were common. Education on pen administration may help to reduce errors.","PeriodicalId":16429,"journal":{"name":"Journal of Medical Toxicology","volume":" ","pages":"278-285"},"PeriodicalIF":2.5,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11288212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ACMT Clinicopathological Conference: The Intoxicated, Poisoned Groundskeeper. ACMT 临床病理学会议：中毒的园丁。

IF 2.5 4区医学

Journal of Medical Toxicology Pub Date : 2024-04-01 Epub Date: 2024-02-20 DOI: 10.1007/s13181-024-00994-2

Antonia Nemanich, Michael Keenan

引用次数: 0

Case Files of the Emory University Medical Toxicology Fellowship: A Patient Presents to the Outpatient Toxicology Clinic with Delusions of Being Poisoned. 埃默里大学医学毒理学研究员病例档案：一名患者因妄想中毒而来到毒理学门诊。

IF 2.5 4区医学

Journal of Medical Toxicology Pub Date : 2024-04-01 Epub Date: 2024-02-20 DOI: 10.1007/s13181-024-00995-1

Matthew Robert Dernbach, Joseph E Carpenter

引用次数: 0

Navigating a Startup Journey: The Journal of Medical Toxicology. 领航创业之旅：医学毒理学杂志》。

IF 2.5 4区医学

Journal of Medical Toxicology Pub Date : 2024-04-01 Epub Date: 2024-03-06 DOI: 10.1007/s13181-024-01002-3

Christian Tomaszewski

引用次数: 0

Welcome to the 2024 ACMT Annual Scientific Meeting. 欢迎参加 2024 ACMT 年度科学会议。

IF 2.5 4区医学

Journal of Medical Toxicology Pub Date : 2024-04-01 Epub Date: 2024-02-26 DOI: 10.1007/s13181-024-00992-4

Michael Toce, Charlotte E Goldfine, Maryann Mazer-Amirshahi, Alison Meyn

引用次数: 0

Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022. 2017-2022 年向美国毒物中心报告的胰高血糖素样肽-1 受体激动剂病例。

IF 2.5 4区医学

Journal of Medical Toxicology Pub Date : 2024-04-01 Epub Date: 2024-02-29 DOI: 10.1007/s13181-024-00999-x

Christopher E Gaw, Hannah L Hays, Cydney A Kemp, Sandhya Kistamgari, Henry A Spiller, Natalie I Rine, Allison L Rhodes, Motao Zhu, Gary A Smith

{"title":"Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022.","authors":"Christopher E Gaw, Hannah L Hays, Cydney A Kemp, Sandhya Kistamgari, Henry A Spiller, Natalie I Rine, Allison L Rhodes, Motao Zhu, Gary A Smith","doi":"10.1007/s13181-024-00999-x","DOIUrl":"10.1007/s13181-024-00999-x","url":null,"abstract":"Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications for management of diabetes and obesity. The objective of this study is to characterize the epidemiology of GLP-1RA cases reported to US poison centers.Methods: We analyzed cases involving a GLP-1RA reported to the National Poison Data System during 2017-2022.Results: There were 5,713 single-substance exposure cases reported to US poison centers involving a GLP-1RA. Most cases were among females (71.3%) and attributable to therapeutic errors (79.9%). More than one-fifth (22.4%) of cases were evaluated in a healthcare facility, including 0.9% admitted to a critical care unit and 4.1% admitted to a non-critical care unit. Serious medical outcomes were described in 6.2% of cases, including one fatality. The rate of cases per one million US population increased from 1.16 in 2017 to 3.49 in 2021, followed by a rapid increase of 80.9% to 6.32 in 2022. Trends for rates of serious medical outcomes and admissions to a healthcare facility showed similar patterns with 129.9% and 95.8% increases, respectively, from 2021 to 2022.Conclusions: Most GLP-1RA cases reported to US poison centers were associated with no or minimal effects and did not require referral for medical treatment; however, a notable minority of individuals experienced a serious medical outcome or healthcare facility admission. The rate of reported cases increased during the study period, including an 80.9% increase from 2021 to 2022. Opportunities exist to improve provider and patient awareness of the adverse effects of these medications.","PeriodicalId":16429,"journal":{"name":"Journal of Medical Toxicology","volume":" ","pages":"193-204"},"PeriodicalIF":2.5,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ensuring the Efficacy and Safety of Approved Medications. 确保批准药物的有效性和安全性。

IF 2.5 4区医学

Journal of Medical Toxicology Pub Date : 2024-04-01 Epub Date: 2024-02-23 DOI: 10.1007/s13181-024-00998-y

Maryann Mazer-Amirshahi, Jon B Cole, Andrew I Stolbach, Jeanmarie Perrone, Lewis S Nelson

引用次数: 0